Unknown

Dataset Information

0

Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.


ABSTRACT: Pulmonary arterial hypertension (PAH) can be found in patients suffering from a loss-of-function mutation of the gene encoding for the activin receptor-like kinase 1 (ALK-1), a bone morphogenetic protein (BMP) type 1 receptor. Interestingly, ALK-1 mutations also lead to hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disease characterized by arteriovenous malformations (AVMs) leading to potentially life-threatening bleeding complications such as epistaxis. Current therapeutic options for both diseases are limited and often only temporary or accompanied by severe side effects. Here, we report of a patient with a mutation of the ALK-1 gene suffering from both HHT and PAH. Recently, it was shown that tacrolimus increased ALK-1 signaling and had beneficial effects in selected end-stage PAH patients. We thus hypothesized that treatment with tacrolimus may prevent disease progression in this patient. Surprisingly, treatment with low-dose tacrolimus dramatically improved his HHT-associated epistaxis but did not attenuate progression of PAH.

SUBMITTER: Sommer N 

PROVIDER: S-EPMC6432681 | biostudies-literature | 2019 Apr-Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Sommer N N   Droege F F   Gamen K E KE   Geisthoff U U   Gall H H   Tello K K   Richter M J MJ   Deubner L M LM   Schmiedel R R   Hecker M M   Spiekerkoetter E E   Wirsching K K   Seeger W W   Ghofrani H A HA   Pullamsetti S S  

Pulmonary circulation 20180927 2


Pulmonary arterial hypertension (PAH) can be found in patients suffering from a loss-of-function mutation of the gene encoding for the activin receptor-like kinase 1 (ALK-1), a bone morphogenetic protein (BMP) type 1 receptor. Interestingly, ALK-1 mutations also lead to hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disease characterized by arteriovenous malformations (AVMs) leading to potentially life-threatening bleeding complications such as epistaxis. Current therapeutic  ...[more]

Similar Datasets

| S-EPMC5888830 | biostudies-other
| S-EPMC8080754 | biostudies-literature
| S-EPMC6510884 | biostudies-literature
| S-EPMC7056052 | biostudies-literature
| S-EPMC9503120 | biostudies-literature
| S-EPMC6351274 | biostudies-literature
| S-EPMC3367481 | biostudies-other
| S-EPMC4622710 | biostudies-literature
| S-EPMC8295629 | biostudies-literature
| S-EPMC7019907 | biostudies-literature